MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1001/archneurol.2009.11

Медицинская библиотека · Archives of neurology · 2009

Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy.

Lozeron Pierre, Denier Christian, Lacroix Catherine, Adams David

Клинический случайСтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVE

To report the long-term follow-up (mean, 41 months; range, 25-55 months) of patients with demyelinating neuropathy occurring after tumor necrosis factor-alpha (TNF-alpha) blocker treatment (infliximab [Remicade], etanercept [Enbrel], and adalimumab [Humira]).

BACKGROUND

Demyelinating neuropathy is a rare adverse event of anti-TNF-alpha therapy. Improvement usually occurs after drug interruption and/or in association with usual treatments for demyelinating neuropathies.

DESIGN

Case report with review of the previously published cases.

SETTING

University hospital in Le Kremlin-Bicêtre, France: tertiary reference center for peripheral neuropathies and national reference center for rare peripheral neuropathies (www.nnerf.fr).

PATIENTS: Five patients (4 men, mean age, 47 years) who developed a demyelinating neuropathy during anti-TNF-alpha therapy.

MAIN OUTCOME MEASURE: Development of neuropathy.

RESULTS

Neuropathy developed early (8 months) after treatment introduction. Various clinical patterns were encountered, including pure sensory neuropathy. Immunomodulating treatments were always required for neuropathy control. Chronic demyelinating neuropathy developed either after change of anti-TNF-alpha drug or spontaneously after treatment discontinuation without any drug reintroduction.

CONCLUSION

Influence of anti-TNF-alpha treatment continuation on the long-term course of neuropathy is variable, suggesting that anti-TNF-alpha treatment withdrawal is not always necessary for neuropathy control.

Для цитирования: Lozeron Pierre, Denier Christian, Lacroix Catherine, Adams David. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy.. Archives of neurology. 2009. DOI: 10.1001/archneurol.2009.11.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.